Full history for every metric is available with a Kvantra account
2seventy bio, Inc. (TSVT)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 44 | 248 | 55 | 91 | 100 | 38 | 48 |
| Operating profit | $m | -115 | -60 | |||||
| Net profit | $m | -323 | -138 | -276 | -254 | -218 | -57 | - |
| EPS reported | $ | -1.10 | - | |||||
| Operating cashflow per share | $ | -1.63 | -1.63 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -1.64 | -1.64 | |||||
| Free cash flow | $m | -86 | -54 | |||||
| Net debt | $m | -175 | -170 | |||||
| Book value equity | $m | 211 | 214 | |||||
| Book value per share | $ | 4.04 | 4.00 | |||||
| Number of shares | m | 52.22 | 53.43 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.73 | 1.24 | |||||
| P/S LTM | x | 4.05 | 5.50 | |||||
| P/FCF LTM | x | -1.79 | -4.91 | |||||
| EV/EBITDA LTM | x | -3.31 | -1.82 | |||||
| EV/Sales LTM | x | 8.61 | 1.98 | |||||
| Earnings Yield LTM | % | -37.29% | -21.93% | |||||
| FCF Yield | % | -55.83% | -20.36% | |||||
| Quality | ||||||||
| ROE | % | -27.16% | -24.56% | |||||
| ROIC | % | -25.33% | -25.33% | |||||
| Operating margin | % | -304.87% | -304.87% | |||||
| Gross margin | % | 40.41% | 40.41% | |||||
| FCF/Sales | % | -226.36% | -226.36% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -62.28% | -32.07% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.35 | -0.23 | |||||
| Net Debt/EBITDA | x | -1.75 | -1.75 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -113.83% | -64.02% | |||||
| Net debt/Equity | x | -0.83 | -0.80 | |||||
| Gross debt/equity | x | 1.16 | 1.12 | |||||
Company overview
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
2seventy bio, Inc. (TSVT)
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free